Ocular Delivery (OcD)

Ocular Delivery (OcD)

The use of drug delivery systems to offer increased safety and utility of ocular therapeutics is a rapidly evolving and ever growing field. Controlled release systems have been employed to both reformulate existing drugs and design new drugs to meet the high potential for commercial interest and patient benefit. The Ocular Delivery Focus Group will support the mission of CRS by engaging researchers, industry representatives, and regulatory experts in the advancement of technologies designed to protect or restore vision. The members of the Focus Group are expected to be paid members of the Controlled Release Society, independent of their membership category. We will also reach out to former or inactive members of CRS and other non-members in the vision research community whose work may benefit from the Focus Group to encourage their participation. This may include notable professional societies in ophthalmology like the Association for Research in Vision and Ophthalmology (ARVO) and the International Society for Eye Research (ISER).

The members of the Focus Group are expected to be paid members of the Controlled Release Society, independent of their membership category.


  • Professor Clive Wilson - Anatomical and Physiological constraints in Ocular Drug Delivery - January 24, 2020 15:00 GMT

Click Here to Read More

  • Andy Whitlock - The Unique Preclinical and Clinical Development Challenges of Ocular Drug Delivery

Click here to read more




Thakur Singh, Ph.D.
Queens University
Vice Chair
Qingguo Xu
Virginia Commonwealth University
Industry Representative
Hunter Chen
Regeneron Pharmaceuticals
Communications Chair
Crystal Shin
Baylor College of Medicine
Secretary Treasurer
Jie Shen
The University of Rhode Island
Trainee Representative
Frances Lasowski
McMaster University
Academic Representative
Rocío Herrero Vanrell
Faculty of Pharmacy Complutense University